Expertise in
73
conditions

Dr. Kumaraswamy Sivakumar

Neurology
Bhsm Rehabilitation LLC
5605 W Eugie Ave, Suite 212and215, 
Glendale, AZ 
Accepting New Patients
Offers Telehealth
Expertise in
73
conditions
Bhsm Rehabilitation LLC
5605 W Eugie Ave, Suite 212and215, 
Glendale, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kumaraswamy Sivakumar is a Neurologist in Glendale, Arizona. Dr. Sivakumar is highly rated in 73 conditions, according to our data. His top areas of expertise are Inclusion Body Myositis, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and Pompe Disease. Dr. Sivakumar is currently accepting new patients.

His clinical research consists of co-authoring 14 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Specialist in AZ
Hospital Affiliations
Yavapai Regional Medical Center
St. Joseph's Hospital And Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EMI Health
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

BHSM REHABILITATION LLC
5605 W Eugie Ave, Suite 212and215, Glendale, AZ 85304
Other Locations
4545 E Shea Blvd, Suite 175, Phoenix, AZ 85028

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drug: Fasudil (WP-0512)
Study Phase: Phase 2
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: ATB200, AT2221
Study Phase: Phase 1/Phase 2
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Biological
Study Drug: HYQVIA
Study Phase: Phase 3
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological
Study Drugs: HYQVIA, Intravenous Immunoglobulin G
Study Phase: Phase 3
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
Enrollment Status: Terminated
Publish Date: June 14, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

14 Total Publications

Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Journal: Journal of neurology
Published: February 17, 2025
Similar Doctors
Expertise in
28
conditions
Dr. Marwan N. Sabbagh
Neurology
Expertise in
28
conditions
Dr. Marwan N. Sabbagh
Neurology

Barrow Neurological Institute

240 West Thomas Road, 3rd Floor, Suite 301, 
Phoenix, AZ 
 (10.6 miles away)
877-857-1920
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marwan Sabbagh is a Neurologist in Phoenix, Arizona. Dr. Sabbagh is highly rated in 28 conditions, according to our data. His top areas of expertise are Alzheimer's Disease, Dementia, Lewy Body Dementia (LBD), Movement Disorders, and Deep Brain Stimulation. Dr. Sabbagh is currently accepting new patients.

Expertise in
17
conditions
Dr. Holly A. Shill
Neurology
Expertise in
17
conditions
Dr. Holly A. Shill
Neurology

Sjhmc Physician Services

500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, 
Phoenix, AZ 
 (10.5 miles away)
602-406-6017
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Holly Shill is a Neurologist in Phoenix, Arizona. Dr. Shill is highly rated in 17 conditions, according to our data. Her top areas of expertise are Parkinson's Disease, Essential Tremor, Movement Disorders, Deep Brain Stimulation, and Tissue Biopsy. Dr. Shill is currently accepting new patients.

Expertise in
23
conditions
Dr. Ashutosh P. Jadhav
Neurology
Expertise in
23
conditions
Dr. Ashutosh P. Jadhav
Neurology

Neurosurgical Associates Ltd

7242 E Osborn Rd, Suite 420, 
Scottsdale, AZ 
 (17.0 miles away)
480-425-8004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ashutosh Jadhav is a Neurologist in Scottsdale, Arizona. Dr. Jadhav is highly rated in 23 conditions, according to our data. His top areas of expertise are Stroke, Subarachnoid Hemorrhage, Brain Aneurysm, Thrombectomy, and Stent Placement.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sivakumar's expertise for a condition
ConditionClose
View All 15 Distinguished Conditions
View All 57 Advanced Conditions
View All 49 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile